NASDAQ:TTNP - Titan Pharmaceuticals Stock Price, Price Target & More

$0.95 0.00 (0.00 %)
(As of 04/25/2018 02:22 AM ET)
Previous Close$0.95
Today's Range$0.9322 - $0.98
52-Week Range$0.93 - $3.05
Volume51,171 shs
Average Volume105,021 shs
Market Capitalization$20.36 million
P/E Ratio-1.36
Dividend YieldN/A
Beta1.39

About Titan Pharmaceuticals (NASDAQ:TTNP)

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. It develops products based on ProNeura, a proprietary long-term drug delivery technology that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for long term maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It is also developing ProNeura-Ropinirole, an implant to provide long-term delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; ProNeura-Triiodothyronine, an implant to provide long-term delivery of triiodothyronine for the treatment of hypothyroidism; and Fanapt, an atypical antipsychotic for the treatment of schizophrenia. The company has a collaboration with Opiant Pharmaceuticals, Inc. to explore development of a novel approach for the prevention of opioid relapse and overdose in individuals with opioid use disorder. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.

Receive TTNP News and Ratings via Email

Sign-up to receive the latest news and ratings for TTNP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TTNP
CUSIPN/A
Phone650-244-4990

Debt

Debt-to-Equity Ratio4.21%
Current Ratio1.86%
Quick Ratio1.86%

Price-To-Earnings

Trailing P/E Ratio-1.36
Forward P/E Ratio-1.90
P/E GrowthN/A

Sales & Book Value

Annual Sales$220,000.00
Price / Sales91.55
Cash FlowN/A
Price / CashN/A
Book Value$0.04 per share
Price / Book23.75

Profitability

EPS (Most Recent Fiscal Year)($0.70)
Net Income$-14,300,000.00
Net Margins-6,654.42%
Return on Equity-248.71%
Return on Assets-129.71%

Miscellaneous

Employees13
Outstanding Shares21,200,000

How to Become a New Pot Stock Millionaire

Titan Pharmaceuticals (NASDAQ:TTNP) Frequently Asked Questions

What is Titan Pharmaceuticals' stock symbol?

Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTNP."

How were Titan Pharmaceuticals' earnings last quarter?

Titan Pharmaceuticals (NASDAQ:TTNP) released its quarterly earnings data on Monday, April, 2nd. The specialty pharmaceutical company reported ($0.17) earnings per share for the quarter, meeting the consensus estimate of ($0.17). The specialty pharmaceutical company earned $0.06 million during the quarter, compared to analyst estimates of $0.23 million. Titan Pharmaceuticals had a negative net margin of 6,654.42% and a negative return on equity of 248.71%. View Titan Pharmaceuticals' Earnings History.

What price target have analysts set for TTNP?

1 brokers have issued twelve-month target prices for Titan Pharmaceuticals' stock. Their predictions range from $2.00 to $2.00. On average, they anticipate Titan Pharmaceuticals' share price to reach $2.00 in the next twelve months. View Analyst Ratings for Titan Pharmaceuticals.

Who are some of Titan Pharmaceuticals' key competitors?

Who are Titan Pharmaceuticals' key executives?

Titan Pharmaceuticals' management team includes the folowing people:
  • Dr. Marc Rubin, Exec. Chairman (Age 63)
  • Mr. Sunil Bhonsle M.B.A., CEO, Pres, Principal Financial Officer, Sec. & Director (Age 68)
  • Dr. Katherine L. Beebe Ph.D., Chief Devel. Officer and Exec. VP
  • Brian E. Crowley, VP of Fin.

Has Titan Pharmaceuticals been receiving favorable news coverage?

Media headlines about TTNP stock have trended somewhat positive on Wednesday, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Titan Pharmaceuticals earned a media sentiment score of 0.20 on Accern's scale. They also assigned news articles about the specialty pharmaceutical company an impact score of 44.92 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Titan Pharmaceuticals?

Shares of TTNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Titan Pharmaceuticals' stock price today?

One share of TTNP stock can currently be purchased for approximately $0.95.

How big of a company is Titan Pharmaceuticals?

Titan Pharmaceuticals has a market capitalization of $20.36 million and generates $220,000.00 in revenue each year. The specialty pharmaceutical company earns $-14,300,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Titan Pharmaceuticals employs 13 workers across the globe.

How can I contact Titan Pharmaceuticals?

Titan Pharmaceuticals' mailing address is 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080. The specialty pharmaceutical company can be reached via phone at 650-244-4990 or via email at [email protected]


MarketBeat Community Rating for Titan Pharmaceuticals (TTNP)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  83 (Vote Outperform)
Underperform Votes:  61 (Vote Underperform)
Total Votes:  144
MarketBeat's community ratings are surveys of what our community members think about Titan Pharmaceuticals and other stocks. Vote "Outperform" if you believe TTNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTNP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Titan Pharmaceuticals (NASDAQ:TTNP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Titan Pharmaceuticals in the last 12 months. Their average twelve-month price target is $2.00, suggesting that the stock has a possible upside of 110.53%. The high price target for TTNP is $2.00 and the low price target for TTNP is $2.00. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.002.002.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.00$2.00$2.00$6.00
Price Target Upside: 110.53% upside25.00% upside25.00% upside224.32% upside

Titan Pharmaceuticals (NASDAQ:TTNP) Consensus Price Target History

Price Target History for Titan Pharmaceuticals (NASDAQ:TTNP)

Titan Pharmaceuticals (NASDAQ:TTNP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/3/2018Roth CapitalSet Price TargetHold$2.00LowView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Titan Pharmaceuticals (NASDAQ:TTNP) Earnings History and Estimates Chart

Earnings by Quarter for Titan Pharmaceuticals (NASDAQ:TTNP)

Titan Pharmaceuticals (NASDAQ:TTNP) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.5 EPS
Next Year EPS Consensus Estimate: $-0.25 EPS

Titan Pharmaceuticals (NASDAQ TTNP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/2/2018Q4 2017($0.17)($0.17)$0.23 million$0.06 millionViewListenView Earnings Details
11/9/2017Q3 2017($0.16)($0.20)$0.17 million$0.04 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.14)($0.17)$0.10 million$0.08 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.15)($0.16)$0.09 million$0.04 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.12)($0.15)$0.62 million$0.04 millionViewN/AView Earnings Details
11/9/2016Q316($0.11)($0.12)$0.25 million$0.03 millionViewListenView Earnings Details
8/9/2016Q2 2016$0.60$0.55$15.00 million$15.00 millionViewN/AView Earnings Details
5/10/2016Q116($0.12)($0.09)ViewListenView Earnings Details
3/15/2016Q415($0.10)($0.11)ViewListenView Earnings Details
11/16/2015Q3 2015($0.13)($0.09)ViewN/AView Earnings Details
8/13/2015($0.02)($0.02)$0.86 million$0.76 millionViewN/AView Earnings Details
5/13/2015($0.03)($0.04)$0.66 million$0.91 millionViewN/AView Earnings Details
3/31/2015($0.01)($0.01)$0.91 million$0.91 millionViewN/AView Earnings Details
11/13/2014($0.02)($0.01)$0.90 million$0.91 millionViewN/AView Earnings Details
8/13/2014($0.02)($0.01)$0.90 million$0.91 millionViewN/AView Earnings Details
5/14/2014Q1 2014($0.11)$0.90 million$0.91 millionViewN/AView Earnings Details
11/15/2013Q3 13($0.01)$2.20 million$2.20 millionViewN/AView Earnings Details
8/14/2013Q2 2013$0.06$0.33$3.80 million$2.20 millionViewN/AView Earnings Details
5/15/2013Q1 2013($0.06)($0.17)$3.80 million$5.17 millionViewN/AView Earnings Details
11/12/2012Q3 2012($0.22)($0.66)ViewN/AView Earnings Details
8/10/2012Q2 2012($0.28)($0.15)ViewN/AView Earnings Details
5/11/2012Q1 2012($2.20)($0.48)ViewN/AView Earnings Details
3/16/2012Q4 2011($0.33)($0.27)ViewN/AView Earnings Details
11/15/2011Q3 2011($0.33)($0.08)ViewN/AView Earnings Details
8/16/2011Q2 2011($0.33)($0.65)ViewN/AView Earnings Details
5/16/2011Q1 2011($0.44)ViewN/AView Earnings Details
3/24/2011Q4 2010($0.29)ViewN/AView Earnings Details
11/15/2010Q3 2010($0.03)ViewN/AView Earnings Details
8/16/2010Q2 2010($0.17)ViewN/AView Earnings Details
5/17/2010Q1 2010($0.03)ViewN/AView Earnings Details
11/10/2008Q3 2008($0.55)($0.56)ViewN/AView Earnings Details
8/12/2008Q2 2008($0.61)($0.73)ViewN/AView Earnings Details
5/12/2008Q1 2008($0.54)ViewN/AView Earnings Details
3/12/2008Q4 2007($0.74)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Titan Pharmaceuticals (NASDAQ:TTNP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Titan Pharmaceuticals (NASDAQ TTNP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.10%
Institutional Ownership Percentage: 6.84%
Insider Trading History for Titan Pharmaceuticals (NASDAQ:TTNP)
Insider Trading History for Titan Pharmaceuticals (NASDAQ:TTNP)

Titan Pharmaceuticals (NASDAQ TTNP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/19/2016Joseph A AkersDirectorBuy13,000$4.85$63,050.008,000View SEC Filing  
7/18/2016Sunil BhonsleCEOBuy10,000$4.96$49,600.00135,578View SEC Filing  
5/31/2016James R McnabDirectorBuy20,000$7.03$140,600.00View SEC Filing  
2/22/2016Sunil BhonsleCEOBuy11,763$3.56$41,876.28125,578View SEC Filing  
1/15/2016Sunil BhonsleCEOBuy5,841$2.72$15,887.52113,815View SEC Filing  
1/13/2016James R McnabDirectorBuy16,363$3.16$51,707.08View SEC Filing  
1/11/2016Marc RubinChairmanBuy5,000$3.25$16,250.00156,317View SEC Filing  
1/11/2016Sunil BhonsleCEOBuy17,000$3.18$54,060.00107,974View SEC Filing  
9/16/2015Sunil BhonslePresidentBuy10,000$0.70$7,000.00491,500View SEC Filing  
8/28/2015Marc RubinChairmanBuy50,000$0.72$36,000.00832,200View SEC Filing  
8/25/2015Sunil BhonslePresidentBuy50,000$0.70$35,000.00481,500View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Titan Pharmaceuticals (NASDAQ TTNP) News Headlines

Source:
DateHeadline
Knight Therapeutics Announces Canadian Regulatory Approval for PROBUPHINE™ for Opioid Drug DependenceKnight Therapeutics Announces Canadian Regulatory Approval for PROBUPHINE™ for Opioid Drug Dependence
globenewswire.com - April 20 at 5:08 PM
TTNP: Molteni Investment Relieves the PressureTTNP: Molteni Investment Relieves the Pressure
finance.yahoo.com - April 12 at 5:17 PM
Titan Pharmaceuticals (TTNP) Forecasted to Earn FY2018 Earnings of ($0.59) Per ShareTitan Pharmaceuticals (TTNP) Forecasted to Earn FY2018 Earnings of ($0.59) Per Share
www.americanbankingnews.com - April 11 at 8:58 AM
Wired News – Conatus to Demonstrate Impact of Pan-caspase Inhibitor IDN-7314 in Reducing Inflammation and Liver Injury in Mouse Model of PSC at EASL Annual MeetingWired News – Conatus to Demonstrate Impact of Pan-caspase Inhibitor IDN-7314 in Reducing Inflammation and Liver Injury in Mouse Model of PSC at EASL Annual Meeting
finance.yahoo.com - April 11 at 8:55 AM
Roth Capital Reiterates $2.00 Price Target for Titan Pharmaceuticals (TTNP)Roth Capital Reiterates $2.00 Price Target for Titan Pharmaceuticals (TTNP)
www.americanbankingnews.com - April 3 at 9:32 AM
AFH revenue up 27.4%, EAST gross sales up 25%, TTNP net loss widensAFH revenue up 27.4%, EAST gross sales up 25%, TTNP net loss widens
investorplace.com - April 3 at 8:43 AM
Titan Pharmaceuticals (TTNP) Posts Quarterly  Earnings Results, Misses Expectations By $0.02 EPSTitan Pharmaceuticals (TTNP) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - April 3 at 7:45 AM
Titan Pharmaceuticals misses by $0.02, beats on revenueTitan Pharmaceuticals misses by $0.02, beats on revenue
seekingalpha.com - April 2 at 5:12 PM
Titan Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial ResultsTitan Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results
www.prnewswire.com - April 2 at 9:03 AM
Takeda Mulls Bid for Shire to Create Global Drug TitanTakeda Mulls Bid for Shire to Create Global Drug Titan
www.wsj.com - March 29 at 5:13 PM
Titan Pharmaceuticals Schedules Conference Call To Review Fourth Quarter And Full Year 2017 Financial ResultsTitan Pharmaceuticals Schedules Conference Call To Review Fourth Quarter And Full Year 2017 Financial Results
finance.yahoo.com - March 26 at 5:02 PM
Titan Pharma (TTNP) Reports Agreement for Acquisition by Molteni of Probuphine in Europe & Other Select Territories - StreetInsider.comTitan Pharma (TTNP) Reports Agreement for Acquisition by Molteni of Probuphine in Europe & Other Select Territories - StreetInsider.com
www.streetinsider.com - March 23 at 5:23 PM
Titan Executes Agreement For Acquisition By Molteni Of Probuphine® In Europe And Other Select TerritoriesTitan Executes Agreement For Acquisition By Molteni Of Probuphine® In Europe And Other Select Territories
finance.yahoo.com - March 21 at 5:22 PM
Soricimed Announces the Appointment of Dr. Marc Rubin and Mr. Vaughn Embro-Pantalony to Board of Directors - GlobeNewswire (press release)Soricimed Announces the Appointment of Dr. Marc Rubin and Mr. Vaughn Embro-Pantalony to Board of Directors - GlobeNewswire (press release)
globenewswire.com - March 21 at 9:23 AM
Biotechnology and Substance Abuse Markets Have Positive Projections - PR Newswire (press release)Biotechnology and Substance Abuse Markets Have Positive Projections - PR Newswire (press release)
www.prnewswire.com - February 21 at 8:41 AM
Titan Announces Amendment To Horizon Loan AgreementTitan Announces Amendment To Horizon Loan Agreement
finance.yahoo.com - February 12 at 9:41 AM
Titan (TTNP) Negotiating with Braeburn for ProbuphineTitan (TTNP) Negotiating with Braeburn for Probuphine
finance.yahoo.com - February 1 at 3:54 PM
Titan In Discussions With Braeburn Regarding US Probuphine® Commercialization - PR Newswire (press release)Titan In Discussions With Braeburn Regarding US Probuphine® Commercialization - PR Newswire (press release)
www.prnewswire.com - January 24 at 8:22 AM
Titan In Discussions With Braeburn Regarding U.S. Probuphine® CommercializationTitan In Discussions With Braeburn Regarding U.S. Probuphine® Commercialization
finance.yahoo.com - January 22 at 9:50 AM
What Should Investors Know About Titan Pharmaceuticals Inc’s (NASDAQ:TTNP) Growth?What Should Investors Know About Titan Pharmaceuticals Inc’s (NASDAQ:TTNP) Growth?
finance.yahoo.com - January 6 at 9:21 AM
ETFs with exposure to Titan Pharmaceuticals, Inc. : December 26, 2017ETFs with exposure to Titan Pharmaceuticals, Inc. : December 26, 2017
finance.yahoo.com - December 26 at 12:47 PM
ETFs with exposure to Titan Pharmaceuticals, Inc. : December 11, 2017ETFs with exposure to Titan Pharmaceuticals, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 3:30 PM
Titan Pharmaceuticals Inc (TTNP.OQ)Titan Pharmaceuticals Inc (TTNP.OQ)
www.reuters.com - December 6 at 11:45 AM
Is There Now An Opportunity In Titan Pharmaceuticals Inc (TTNP)?Is There Now An Opportunity In Titan Pharmaceuticals Inc (TTNP)?
finance.yahoo.com - December 5 at 11:19 AM
Titan Pharmaceuticals, Inc. (TTNP) Forecasted to Earn FY2019 Earnings of ($0.27) Per ShareTitan Pharmaceuticals, Inc. (TTNP) Forecasted to Earn FY2019 Earnings of ($0.27) Per Share
www.americanbankingnews.com - December 2 at 12:58 AM
ETFs with exposure to Titan Pharmaceuticals, Inc. : November 30, 2017ETFs with exposure to Titan Pharmaceuticals, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 3:31 PM
Titan Pharma (TTNP) Enters Pact with Molteni to Market Probuphine in EuropeTitan Pharma (TTNP) Enters Pact with Molteni to Market Probuphine in Europe
www.streetinsider.com - November 29 at 3:31 PM
Titan Pharmaceuticals, Inc. :TTNP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017Titan Pharmaceuticals, Inc. :TTNP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 10:59 AM
Titan Pharmaceuticals Partners With Molteni To Market Probuphine® In EuropeTitan Pharmaceuticals Partners With Molteni To Market Probuphine® In Europe
finance.yahoo.com - November 28 at 8:31 AM
Titan Pharma (TTNP) Granted European Medicines Agency ... - StreetInsider.comTitan Pharma (TTNP) Granted European Medicines Agency ... - StreetInsider.com
www.streetinsider.com - November 27 at 3:20 PM
European Medicines Agency Accepts Titan Pharmaceuticals Marketing Authorization Application For Probuphine®European Medicines Agency Accepts Titan Pharmaceuticals' Marketing Authorization Application For Probuphine®
finance.yahoo.com - November 27 at 9:06 AM
Titan Pharmaceuticals reports 1Q lossTitan Pharmaceuticals reports 1Q loss
marketbeat.com - May 10 at 7:28 AM
FDA Approves New Opioid Addiction Treatment Tech - BenzingaFDA Approves New Opioid Addiction Treatment Tech - Benzinga
www.benzinga.com - May 27 at 9:49 PM
FDA Approves Titan Pharmas (TTNP) Buprenorphine Implant for Treatment of Opioid Dependence - StreetInsider.comFDA Approves Titan Pharma's (TTNP) Buprenorphine Implant for Treatment of Opioid Dependence - StreetInsider.com
www.streetinsider.com - May 26 at 9:34 PM
The First Implant to Treat Opioid Addiction Just Got ApprovedThe First Implant to Treat Opioid Addiction Just Got Approved
fortune.com - May 26 at 6:47 PM
After-Hours Stock Movers 05/23: (AGLE) (PLCM) (NDSN) Higher; (SSW) (WMGI) (BAH) Lower (more...)After-Hours Stock Movers 05/23: (AGLE) (PLCM) (NDSN) Higher; (SSW) (WMGI) (BAH) Lower (more...)
www.streetinsider.com - May 24 at 2:06 AM
TITAN PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD DisclosureTITAN PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure
biz.yahoo.com - May 19 at 6:13 AM
TITAN PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly ReportTITAN PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - May 10 at 1:43 PM
Q1 2016 Titan Pharmaceuticals Inc Earnings Release - Time Not SuppliedQ1 2016 Titan Pharmaceuticals Inc Earnings Release - Time Not Supplied
biz.yahoo.com - May 10 at 7:07 AM
TITAN PHARMACEUTICALS INCTITAN PHARMACEUTICALS INC
www.finanznachrichten.de - May 4 at 9:58 PM
Titan Pharma to Present Phase 3 Data of Probuphine at ASAM Annual Conference - BenzingaTitan Pharma to Present Phase 3 Data of Probuphine at ASAM Annual Conference - Benzinga
www.benzinga.com - April 15 at 10:55 PM
TITAN PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsTITAN PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - February 22 at 6:04 AM

SEC Filings

Titan Pharmaceuticals (NASDAQ:TTNP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Titan Pharmaceuticals (NASDAQ:TTNP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Titan Pharmaceuticals (NASDAQ TTNP) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.